Journal of Health and Medical Sciences
Published: 29 March 2019
Overview of Kawasaki Disease in Albaha Area, Saudi Arabia
Abdulmajid Mustafa Almawazini, MD, Ph.D., Sinan Alnashi, CABP, SSCP., Ali A. Alsharkawy, CABP, SSCP., Mohammad Abdulmajid Almawazini, Hazem Abdulmajid Almawazini, Mohammed Saad Alzahrani, Saad Ali M. Alqahtani
King Fahad Hospital, Kingdom of Saudi Arabia
Download Full-Text Pdf
Background: Kawasaki disease (KD), an acute, febrile, self-limiting vasculitis of unknown etiology, is a disease that predominantly affects medium- and small-sized arteries of infants and preschool children. Objectives: This study aimed to evaluate the presentation and clinical course, diagnosis, management, outcomes, and complications of KD, as well as the presence of abnormal laboratory values therein, among children admitted to King Fahad Hospital, Albaha, Saudi Arabia. Methods: This observational, hospital-based retrospective cohort study was conducted at the Department of Pediatrics and Neonatology, King Fahad Hospital Albaha, from 2008 to 2018. Those with both complete and incomplete KD were considered. The diagnostic criteria for KD were based on the European and American Heart Association recommendations. Results: The prevalence of KD in Albaha area was 0.6%. It was more common among in male patients (60%) than in female patients (40%). 85% of patients satisfied the diagnostic criteria for complete KD. Among the cases included, 60% were diagnosed during winter and spring. Cardiac abnormalities confirmed through echocardiography were documented in 22.5% of the patients. Abnormal laboratory results were significantly common among those with incomplete KD. Conclusion: Majority of patients fulfilled diagnostic criteria of complete KD, and the presence of coronary artery abnormalities consisted with other international published studies. All patients successfully completely recovered during follow-up, and no mortality was documented.
1. Brian W. McCrindle. Anne H. Rowley. Jane W. Newburger. Jane C. Burns. Anne F. Bolger Michael Gewitz. Annette L. Baker. Mary Anne Jackson. Masato Takahashi. Pinak B. Shah. Tohru Kobayashi. Mei-Hwan Wu. Tsutomu T. Saji. Elfriede Pahl. And On behalf of the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association Originally published29 Mar 2017 https://doi.org/10.1161/CIR.0000000000000484 Circulation. 2017; 135:e927–e999.
2. Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Pilkington C, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Brogan P, Beresford MW. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology (Oxford). 2018 Dec 7. doi: 10.1093/rheumatology/key344.
3. Manlhiot C, Mueller B, O'Shea S, Majeed H, Bernknopf B, Labelle M, Westcott KV, Bai H, Chahal N, Birken CS, Yeung RSM, McCrindle BW. Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution. PLoS One. 2018 Feb 7;13(2):e0191087. doi: 0.1371/journal.pone.0191087, e Collection 2018.
4. Fabi M, Corinaldesi E, Pierantoni L, Mazzoni E, Landini C, Bigucci B, Ancora G, Malaigia L, Bodnar T, Di Fazzio G, Lami F, Valletta E, Cicero C, Biasucci G, Iughetti L, Marchetti F, Sogno Valin P, Amarri S, Brusa S, Sprocati , Maggiore G, Dormi A, Lanzoni P, Donti A, Lanari M. PLoS One. Gastrointestinal presentation of Kawasaki disease: A red flag for severe disease? eCollection 2018 Sep 4;13(9): e0202658. doi: 10.1371/journal.pone.0202658.
5. Matteo Botti,* Giorgio Costagliola, and Rita Consolini. Typical Kawasaki Disease Presenting With Pancreatitis and Bilateral Parotid Gland Involvement: A Case Report and Literature Review. Front Pediatr. 2018; 6: 90. Published online 2018 Apr11. doi: 10.3389/ fped.2018.00090.
6. Falcini F, Ozen S, Magni-Manzoni, Zulian F, et al. Discrimination between incomplete and atypical Kawasaki syndrome versus other febrile diseases in childhood: results from an international registry-based study. Clin Exp Rheumatol 2012, 30:799–804.
7. Vignesh Pandiarajan, Singh Surjit. https://www.ncbi.nlm.nih.gov/pubmed/29657882 Perianal skin peeling: An important clinical pointer toward Kawasaki disease. Eur J Rheumatol 2018 Mar; 5(1):81-82. doi: 10.5152/eurjrheum. 2017.17010. Epub 2017 Aug 29.
8. Kim JO, Kim YH, Hyun MC. Comparison between Kawasaki disease with lymph-node-first presentation and Kawasaki disease without cervical lymphadenopathy. Korean J Pediatr. 2016 Feb;59(2):54-8. doi: 10.3345/kjp. 2016.59.2.54. Epub 2016 Feb 29.
9. Eleftheriou D, Levin M, Shingadia D, et al. Management of Kawasaki disease. Archives of Disease in Childhood. 2014;99(1):74-83.
10. Okada K, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, Yamamoto T, Nishigaki T, Kurotobi S, Sano T; Osaka Kawasaki Disease Study Group. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168:181–185. doi: 10.1007/s00431- 008-0727-9.
11. Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012;129:e17–e23. doi: 10.1542/peds.2011-0148.
12. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008; 153:833–838. doi: 10.1016/j.jpeds. 2008.06.011.
13. Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, Watanabe K, Watanabe S, Uese K, Kanegane H, Origasa H, Ichida F, Roth J, Miyawaki T, Saji T. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res. 2009; 65:696–701. doi: 10.1203/PDR, 0b013e31819ed68d.
14. Yun SH, Yang NR, Park SA. Associated symptoms of Kawasaki disease. Korean 2011; Circ J 41:394–398.
15. McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, Vetter VL, Gersony WM, Mitchell PD, Newburger JW; Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Pediatric Heart Network Investigators. Circulation. 2007 Jul 10;116(2):174-9.
16. Gorczyca D, Postepski J, Olesinska E, Lubieniecka L, Lacho´r-Motyka I, Opoka-Winiarska V, Gruenpeter A. The clinical profile of Kawasaki disease of children from three Polish centers: a retrospective study. Rheumatol Int (2014) 34:875–880.
17. Manlhiot C, Christie E, McCrindle BW, Rosenberg H, Chahal N, Yeung RS. Complete and incomplete Kawasaki disease: two sides of the same coin. Eur J Pediatr; 2012; 171:657-662.